Welcome to ZimVie | Dental, Spine and Bone Healing Solutions He has more than 25 years of experience across all areas of finance within medtech and other industries. Such statements are based upon the current beliefs, expectations and assumptions of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially from the forward-looking statements. Our Story | Company Overview | ZimVie Adjusted EBITDA of $31.3 million or 13.4% of third-party sales reflects a decrease of 110 basis points from 14.5% in the prior year period. [Operator Instructions] Please be advised that todays conference is being recorded. Explore Careers. ZimVie Completes Separation from Zimmer Biomet; Announces Board of and WESTMINSTER, Colo., Feb. 7, 2022 /PRNewswire/ -- ZimVie, the intended standalone, publicly traded entity to be spun off from Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), will host its inaugural Investor Day today, February 7, 2022, from 11:00 a.m. to approximately 2:00 p.m. Eastern Time. The spine portfolio includes: Mobi-C Cervical Disc: a cervical disc approved to treat more than one level of the cervical spine. Key Executives. Zimmer Biomet Announces Filing of Form 10 Registration - Insider Although the realization of many of these projects will manifest themselves in the income statement over coming quarters we are seeing an immediate benefit to liquidity and financial flexibility, as I just discussed. Shifting to our two segments, Global dentals third-party net sales were $118.2 million representing a 1.8% decrease on a reported basis and a 2.9% increase in constant currency when compared to the prior year period, primarily driven by implants and digital dentistry net sales growth and an extra selling day in Q2 of 2022, offset by foreign currency exchange headwinds, mainly net sales denominated in euro. So, I think you will continue to see that theme. Robbie thanks for your questions. We are feeling really optimistic about the business. Our vision is that everyone deserves to feel better, healthier and stronger. And as we mentioned before, we are looking to operationalize the business and look to really take out a lot of waste. . Our Story | Company Overview | ZimVie These items may vary greatly from year to year and could significantly impact our results as reported in accordance with GAAP. See "Forward-Looking Non-GAAP Financial Measures" below. Vafa serves on the board of directors of Baylis Medical and Eptam Precision. Thanks Vafa and good afternoon everyone. But not necessarily when we go to visit the customers, we are not seeing a loss of a customer, we are seeing an absentee customer on vacation for a good reason. investors, and communities. As CEO, Vafa leads ZimVie's overall global operations and strategic vision. Head-to-head connectors provide multi-planar motion, allowing for off-axis screw head positioning. Our Contacts. Bens experience spans all aspects of Operations, including manufacturing, quality, supply chain management, sourcing, distribution, continuous improvement, and facilities. Rich most recently served as Chief Financial Officer of Breg, Inc. and previously held senior leadership roles at Orthofix International, Solera Holdings, Flowserve Corporation, and Coopervision Inc. Mike is responsible for providing strategic direction through developing and operationalizing strategic plans and initiatives to accelerate growth and drive ZimVies competitive advantage. Good afternoon and thank you all for joining us. Maybe speak to where you are seeing the cost savings? ZimVie is a global life sciences leader in the dental and spine markets that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to treat a wide range of spine pathologies and support dental tooth replacement and restoration procedures. I want to close our call by looping back to the positive policy decision from Anthem Blue Cross Blue Shield for The Tether, expanding potential treatment eligibility within their 30 million plus members covered under Anthem Blue Crafter Shield. Thus, we are maintaining our adjusted EBITDA margin range of 13.1% to 13.6%. Dental Solutions | ZimVie It is probable that these forward-looking non-GAAP financial measures may be materially different from the corresponding GAAP financial measures. His experience includes serving as Vice President, IT, Global Applications Services, and Vice President, divisional CIO, for the Covidien business unit at Medtronic and leading IT transformation projects for The Hackett Group. Why White Sox' Garrett Crochet might slot in 'hybrid' role in 2023 With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. ZimVie Hosts Inaugural Investor Day; Provides 2022 Financial Outlook Bard, Smith & Nephew, Sterigenics International, and Microport Orthopedics. Maybe to start, just so we have a framework of guidance here, what were you assuming for currency in the prior guidance range, whats the currency headwind now assumed in this, just so we could get a better sense of whats FX and whats underlying performance? Press Releases | ZimVie Inc. Rich Heppenstall EVP, CFO Rich oversees all areas of ZimVie's finance and accounting organization and investor relations. Investor Relations | ZimVie Inc. Thank you very much for joining the call. ZimVie Inc. (ZIMV) Q3 2022 Earnings Call Transcript Please go ahead. Tim Doherty - Zimvie | ZoomInfo 774-284-1606 . Products and Services Angulated Screw Channel (ASC) As it relates to the segments, we now expect full year 2022 net sales growth in the mid-single digits on a constant currency basis for our Dental business. Read More. Zimmer gives investors first look at its dental and spine spinoff Good day and thank you for standing by. Outside of the U.S., sales of $48.0 million decreased by 8.9% on a reported basis but increased 1.9% when excluding the impact of currency. Is ZimVie Going to Be the Breakout Medtech Company of 2022? I would also like to highlight that we improved our cash balance by approximately $25 million sequentially from first quarter end through second quarter end, closing June with $130 million in cash and equivalents. Turning to our bottom line expectations, we are revising our full year 2022 adjusted earnings per share outlook to a range of $1.80 to $2 per share from $2.10 to $2.30 per share previously. For full biographies on each of the directors, please visit ZimVie's investor relations website. As you recall, our dental business is almost half outside of the U.S. And so we are seeing over $30 million of FX headwind in the guidance revision. As I mentioned earlier, we have the fortune of being a leading player in two substantial and growing markets. But I do believe the summer is slow and we dont see, especially outside of the U.S. Ann joined ZimVie from Zimmer Biomet, where she led Quality and Regulatory Affairs for Robotics and several other business units. He has been transforming business through technology for more than 25 years, both as a consultant and in executive-level corporate IT roles. Second Quarter Was A Disappointment However, for Q2/2022, ZimVie delivered a disappointing report. CopiOs Bone Void Filler Indux Cancellous Sponge and Cortical Strip InterGro DBM Family In 2021, the spine segment is estimated to make up about 56% of revenues, with . Yes. How should we think about where the biggest pressure points are? Forward-Looking Non-GAAP Financial MeasuresThis press release includes certain forward-looking non-GAAP financial measures for the year ending December 31, 2022 that differ from financial measures calculated in accordance withU.S.generally accepted accounting principles ("GAAP"). Just 3 weeks ago, the family got word that insurance would cover the procedure due to the updated policy deemed in the treatment medically necessary for indicated patients. Okay. Investor's Business Daily S&P 500 Falls Below Key Level On Elections, Tesla, Bitcoin; CPI Inflation Report Looms The S&P 500 fell below its 50-day line on election results, Tesla, Bitcoin and more. These items may vary greatly from year to year and could significantly impact our results as reported in accordance with GAAP. Based on approximately 209.2 million shares of Zimmer Biomet common stock outstanding as of February 1, 2022, and without accounting for cash to be issued in lieu of fractional shares, ZimVie expects that a total of approximately 20.92 million shares of ZimVie common stock will be distributed to Zimmer Biomet's stockholders and approximately 5. . This conference call contains time-sensitive information and is accurate only as of the live broadcast today, August 10, 2022. Before I close and hand back over to Vafa I want to underscore that we were to launch a number of operational initiatives in the 4 months since spin to control operating expenses, rightsize our business, rationalize our real estate and geographic footprint and monetize the strength of assets on our balance sheet. He brings more than 25 years of experience in medical devices, having held leadership roles at Medtronic, Covidien, Cardinal Health, and Baxter. Rich, anything else you think. ZimVie is a brand new, publicly traded global life sciences company with a portfolio of trusted brands and products, led by a team of energetic and seasoned experts. However, we are not allowing a challenging macro environment to detract from our focus on strengthening our foundation and positioning to drive future growth. Our Spine business comprises the broad portfolio of spine implants, instruments and biologics as well as bone healing solutions. "As an independent company, we will be uniquely positioned to expand the reach of our solutions and execute on opportunities to drive sustainable growth and long-term shareholder value as we bring renewed energy and strategic focus to our brands and products that are trusted all over the world.". ZimVie to Report Second Quarter 2022 Financial Results on August 10, 2022 12 Jul '22 ZimVie Announces Positive Policy Decision from Anthem for Anterior Vertebral Body Tethering, Expanding Coverage to 30+ Million Lives 16 Jun '22 ZimVie Announces Launch of Two Next-Generation Dental Solutions in the United States 05 May '22 This includes approximately $22 million of cash earmarked to settle certain post-spin-related transactions and to fund ERP implementations to decouple from our prior parent company. Third Quarter 2022 Zimmer Biomet Announces Third Quarter 2022 Financial Results International toll-free and local numbers View All Results View Fact Sheet Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. WARSAW, Ind. Im on the call today with Rich Heppenstall, our Chief Financial Officer. t***@zimvie.com. ZimVie is a global life sciences leader in the dental and spine markets that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to treat a wide range of spine pathologies and support dental tooth replacement and restoration procedures. What we are seeing right now with the euro basically close to parity, we are seeing over $30 million of FX headwind. She brings more than 25 years of quality and regulatory experience in the medical device, pharmaceutical, nutritional, and biologics sectors. I think I said low-single digit, I meant low-double digit decline, my fault. Thanks a lot. You may now disconnect. Both the T3 PRO and Encode Emergence reflect significant innovation to ZimVies previous products and promised an optimized implant experience for both dentists and patients. Virage OCT Spinal Fixation System | ZimVie Spine Products Media Contact Information: ZimVie Laura Driscoll Laura.Driscoll@ZimVie.com (774). Touching on working capital and liquidity, we are in the early stages of capitalizing on the strength of assets on our balance sheet with a focus on optimizing the allocation of capital and the monetization of certain assets to drive cash and thus increase financial flexibility. Before joining Zimmer Biomet in 2009, Heather was a Partner with the law firm now known as Faegre Drinker Biddle & Reath LLP. Strong double-digit implant growth in the U.S. was fueled by pull-through from our digital dentistry and biomaterials offerings and leveraging our medical education programs, but was partially overshadowed by a more challenging macroeconomic environment outside of the U.S., particularly in Europe. Laura leads ZimVies Global Communications Team, which includes marketing communications, as well as corporate philanthropy. Forward-Looking Non-GAAP Financial MeasuresThis press release includes certain forward-looking non-GAAP financial measures for the year ending December 31, 2022 that differ from financial measures calculated in accordance with U.S. generally accepted accounting principles ("GAAP"). ZimVie Inc. (NASDAQ:ZIMV) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET, Vafa Jamali - President and Chief Executive Officer, Rich Heppenstall - Chief Financial Officer. Continued uncertainty due to the ongoing COVID-19 pandemic could materially impact the company's projections. Print Page Email Alerts Stock Information ZimVie is a global life sciences leader in the dental and spine markets that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to treat a wide range of spine pathologies and support dental tooth replacement and restoration procedures. The way I think about it is if Q3 sequentially is our lower quarter for dental, and so what we expect to see is a kind of a modest decline in Q3 due to seasonality and then Q4 is typically our strongest quarter. Welcome to ZimVie | Dental, Spine and Bone Healing Solutions Not fully diluted for 2022. ZimVie is a global medical technology leader dedicated to restoring life for dental and spine patients, and we participate in a $20 billion global market opportunity across those markets. ZimVie is a global life sciences leader in the dental and spine markets that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to treat a wide range of spine pathologies and support dental tooth replacement and restoration procedures. Are you really holding spend tight just cost line and are you more limiting spend, or are you reallocating spend that would have been helped to drive the top line? Presentations August 10, 2022 ZimVie Second Quarter 2022 Financial Results and Supplemental Information3.5 MB May 5, 2022 ZimVie First Quarter 2022 Financial Results3.6 MB February 22, 2022 ZimVie Corporate Fact Sheet3 MB February 7, 2022 ZimVie Investor Day Presentation5.3 MB Print Page Email Alerts RSS Feeds Contact IR So, internally speaking, we are continuing to make some progress against some of these operational gains we have made. Reconciliations of these measures to the most directly comparable GAAP financial measures are included within the earnings release and/or the investor deck issued today found on the Investor Relations section of the companys website, zimvie.com. Heather oversees ZimVies Legal and Compliance functions and serves as Secretary to the board of directors. In conjunction with the event, ZimVie is providing the following full-year 2022 financial guidance: * These measures are non-GAAP financial measures for which a reconciliation to the most directly comparableGAAP financial measure is not available without unreasonable efforts. The event will feature a live Q&A panel following speaker presentations. The company first announced the spinoff in February of 2021. Terms of the Separation . Investor Relations. Based on recent market data, we see T3 PRO capturing modest early share in the premium implant segment. Prior to the announced spin-off Zimmer Biomet struggled with quality control and supply chain problems for about a year at that point, and those challenges had created investor frustration that ultimately led to former CEO David Dvorak's resignation in July 2017. During the quarter, we realized a tax benefit of $6.3 million on an adjusted basis or approximately $0.24 per share due in large part to account for income tax previously recognized for intercompany inventory when we were part of Zimmer Biomet. For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet. Prior to Fresenius, she spent 10 years in key communication roles at Covidien, and then Medtronic after the acquisition of Covidien. Forward-looking statements speak only as of the date they are made, and we expressly disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ZIMV Stock Forecast, Price & News (ZimVie) - MarketBeat Dental Solutions | ZimVie ZIMVIE INC Chief Investor Relations Officer Salary | Salary.com We drove cash flow improvement through greater fiscal discipline, including spending scrutiny and monetization of certain aspects of our balance sheet, as Rich will detail shortly. ET). Our results in the quarter were impacted to some extent by shortage in the facility staffing and the elective nature of some of our procedures, damage which many of our peers have also stated. ZimVie Inc. (ZIMV) Q3 2022 Earnings Call Transcript Today, I want to highlight the story of a 13-year old male patient with scoliosis for whom coverage was the prior barrier to therapy, although the doctors at Childrens Hospital Colorado recommended VBT, his original claim and appeal were denied. And with that, I will turn the call over to Vafa Jamali, President and Chief Executive Officer of ZimVie. Investor Relations Stock Price $8.20 0.00 (0.00%) This inventory is nontaxable to ZimVie as it is sold. Contact. Careers; Investors; Global Contacts . Safety ZimVie Inc. (ZIMV) CEO Vafa Jamali on Q1 2022 Results - Seeking Alpha On the spine side of things, we expect the balance of the year to be in the low-single digit decline. In addition, ZimVie will host a virtual Investor Day on Monday, February 7, 2022 from 11:00 a.m. to approximately 3:00 p.m. Eastern Time. Date Description Download; Date Nov 05, 2022 : Description Zimmer Biomet Announces One-Year Data from mymobility Clinical Study at 2022 AAHKS Annual Meeting: Download: Date Nov 02, 2022 : Description Zimmer Biomet Announces Third Quarter 2022 Financial Results: Download: Date Oct 05, 2022 : Description Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2022 Financial Results ZimVie Hosts Inaugural Investor Day; Provides 2022 Financial Outlook Stock Price. Investor Relations Stock Price $7.63 0.00 (0.00%)
Rac Rally 2021 Spectators, Yamazaki Distillery Reserve, Most Beautiful Places In Iceland, Us Military Base In Germany, Fitness+meditation App, Are Sprouted Lentils A Complete Protein, Shawn Elliott Football Camp, List Of Minecraft Building Blocks, Plus Size Flowy Tankini Tops, Atlanta Maternal Fetal Medicine Stockbridge, Plus Size Flowy Tankini Tops, Girlfriend Not Replying To Texts After Fight,